Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial

Diabetes - GeneralType 2 Diabetes
Do you want to read an article? Please log in or register.